Shankar Musunuri, PhD, MBA
Chairman of the Board, CEO and Co-founder
Dr. Musunuri is the Co-founder, Chairman and CEO of Ocugen, Inc. Dr. Musunuri is a seasoned biotech veteran with over 24 years of results-driven experience that includes advancing and commercializing a diverse portfolio of products for numerous companies ranging from “Big Pharma” to novel start-up biotechs. As a serial entrepreneur, Dr. Musunuri has raised upwards of $180 million in capital. Dr. Musunuri was the former President, Chief Executive Officer and board member of ioGenetics, Inc. Prior to ioGenetics, Dr. Musunuri was a Founder, President, Chief Executive Officer, and a board member of Nuron Biotech, Inc. Previously, Dr. Musunuri spent nearly fifteen years at Pfizer where he had held various positions of increasing leadership and responsibility. At Pfizer, his extensive experience in product launches and product life-cycle management included the most successful launch in vaccine history, Prevnar 13®, where he was played a key role as the Global Operations Team Leader. Prior to Pfizer, Dr. Musunuri worked for Amylin Pharmaceuticals. Dr. Musunuri has won numerous company, society and organizational awards.
Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy. He serves on the Advisory Board of Fuqua’s Center for Entrepreneurship and Innovation.
Uday Kompella, PhD
Co-founder and Chief Scientific Officer
Dr. Kompella is an Ocugen Co-founder and a member of the board. He is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado-Anschutz Medical Campus, with research interests in the areas of drug discovery, drug delivery, and nanotechnology for treating a variety of degenerative, neovascular, and inflammatory disorders including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and cancers. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the Association for Research in Vision and Ophthalmology (ARVO) and serves as the Editor-in-Chief for the journal Expert Opinion on Drug Delivery. Also, he is an editor for the journals, Pharmaceutical Research and the Journal of Ocular Pharmacology and Therapeutics. Dr. Kompella is a recipient of the Distinguished Scientist Award (University of Nebraska Medical Center), Distinguished Teacher Award (University of Nebraska Medical Center), and Dean’s Mentoring Award (University of Colorado Anschutz Medical Campus). He is also a recipient of the ARVO Foundation for Eye Research/Pfizer Ophthalmics/Carl Camras Translational Research Award in Ophthalmology. Dr. Kompella obtained his PhD in Pharmaceutical Sciences from the University of Southern California.